FDA Declares Tirzepatide Shortage Over, Halting Compounded Versions
FDA Stands firm: Tirzepatide Shortage Over, Compounded Versions Face Deadline
The Food adn Drug Administration (FDA) reaffirmed Thursday that the shortage of tirzepatide, the key ingredient in popular weight-loss drugs Mounjaro and Wegovy, is officially over. This decision means moast compounding pharmacies will have 90 days to cease production of compounded versions of the drug.
The move comes after the Outsourcing Facilities Association, a trade group representing compounding pharmacies, challenged the FDA’s initial declaration in October that the shortage had ended. the association argued that tirzepatide remained scarce, prompting the FDA to re-evaluate the situation.
“FDA may still take action regarding violations of any other statutory or regulatory requirements, such as to address findings that a product may be of substandard quality or otherwise unsafe,” an FDA spokesperson said.
A temporary Solution, Not a Long-Term Fix
Compounded tirzepatide gained traction as a more affordable alternative to brand-name medications like Mounjaro and Wegovy, which have seen soaring demand and limited supply. Compounding pharmacies, under FDA guidelines, are permitted to create copies of brand-name drugs during declared shortages. However, pharmaceutical companies have consistently opposed this practice, raising concerns about the safety and efficacy of compounded medications.
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, acknowledged the FDA’s decision but emphasized that the legal battle is far from over. “Though the agency is doubling down on its October 2 shortage resolution, there’s still litigation out there,” Brunner said.
Lilly Celebrates,Compounding Pharmacies Face Uncertainty
The FDA’s decision marks a victory for Eli Lilly,the maker of Mounjaro and Wegovy,which has consistently maintained that the tirzepatide shortage had been resolved. A Lilly spokesperson emphasized the need for all unauthorized production of tirzepatide to cease.
“Anyone marketing or selling unapproved tirzepatide knockoffs must stop,” the spokesperson stated.
Simultaneously occurring, compounding pharmacies face a looming deadline. Those producing compounded tirzepatide in smaller quantities have untill february 18 to distribute their remaining stock. Larger-scale compounding facilities, known as 503B facilities, have an additional month, with a deadline of march 19.
Semaglutide Shortage Persists
While the tirzepatide shortage appears to be easing, the FDA confirmed that semaglutide, the active ingredient in Novo Nordisk’s ozempic and Wegovy, remains in short supply.
The ongoing debate surrounding compounded medications highlights the complex challenges of balancing patient access to affordable treatments with the safety and quality standards upheld by pharmaceutical companies and regulatory agencies.
FDA Stands Firm: Tirzepatide Shortage Over, compounded Versions Face Deadline
The Food and Drug Management (FDA) reaffirmed Thursday that the shortage of tirzepatide, the key ingredient in popular weight-loss drugs Mounjaro and Wegovy, is officially over. This decision means most compounding pharmacies will have 90 days to cease production of compounded versions of the drug.
The move comes after the Outsourcing Facilities Association, a trade group representing compounding pharmacies, challenged the FDA’s initial declaration in october that the shortage had ended. The association argued that tirzepatide remained scarce, prompting the FDA to re-evaluate the situation.
“FDA may still take action regarding violations of any other statutory or regulatory requirements, such as to address findings that a product may be of substandard quality or otherwise unsafe,” an FDA spokesperson said.
A Temporary Solution, Not a Long-Term Fix
Compounded tirzepatide gained traction as a more affordable alternative to brand-name medications like mounjaro and Wegovy, which have seen soaring demand and limited supply. Compounding pharmacies, under FDA guidelines, are permitted to create copies of brand-name drugs during declared shortages. However, pharmaceutical companies have consistently opposed this practice, raising concerns about the safety and efficacy of compounded medications.
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, acknowledged the FDA’s decision but emphasized that the legal battle is far from over.”Though the agency is doubling down on its October 2 shortage resolution, there’s still litigation out there,” Brunner said.
Lilly Celebrates, compounding Pharmacies face Uncertainty
The FDA’s decision marks a victory for Eli Lilly, the maker of Mounjaro and Wegovy, which has consistently maintained that the tirzepatide shortage had been resolved. A Lilly spokesperson emphasized the need for all unauthorized production of tirzepatide to cease.
“Anyone marketing or selling unapproved tirzepatide knockoffs must stop,” the spokesperson stated.
Concurrently, compounding pharmacies face a looming deadline.Those producing compounded tirzepatide in smaller quantities have until February 18 to distribute their remaining stock. Larger-scale compounding facilities, known as 503B facilities, have an additional month, with a deadline of March 19.
semaglutide Shortage Persists
While the tirzepatide shortage appears to be easing, the FDA confirmed that semaglutide, the active ingredient in Novo Nordisk’s Ozempic and wegovy, remains in short supply.
The ongoing debate surrounding compounded medications highlights the complex challenges of balancing patient access to affordable treatments with the safety and quality standards upheld by pharmaceutical companies and regulatory agencies.